Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

A groundbreaking cancer drug nabs fast OK This

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155444
(Total Views: 841)
Posted On: 05/12/2020 9:00:53 AM
Avatar
Posted By: Rubraquercus
A groundbreaking cancer drug nabs fast OK

This could help us get our arms around what CYDY may be worth in a buy out...

UPDATED:
A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind

Eli Lilly $LLY has scored the fast FDA approval it was gunning for when the pharma giant plunked down $8 billion to acquire Loxo Oncology back at the beginning of 2019. Regulators stamped their OK on selpercatinib, which can now be marketed as Retevmo to patients suffering from 3 different types of cancers all driven by the same gene alteration.

The approval marks another win for advocates of rapid development, with the Loxo team jumping from their first treatment to an approval on Phase I/II data in 3 short years. And it comes just 3 months after the FDA’s cancer group handed Lilly a priority review, indicating that the agency still finds it easy to reward advances in the field with speedy answers — despite the pandemic.

For Lilly, the drug OK also marks a rare first place finish, but Blueprint Medicines $BPMC is expected to quickly counter with new data at ASCO on a rival that is one step behind the pharma giant.

The pharma player got the marketing ball rolling with a $20,600 per month price on the therapy.

But they don’t have a lock on best-in-class status. As Steve Scala at Cowen noted Monday morning:

The label contains positives (line agnostic, increased efficacy in thyroid cancer) and negatives (safety warnings including liver monitoring, incremental downtick in lung efficacy). All told, the label is incrementally worse than hoped. Long-term durability data is now more important.

The FDA action covers RET fusion-positive non-small cell lung cancer and thyroid cancer, along with RET-mutant medullary thyroid cancer. In the absence of an approved test to spot the alteration, Lilly suggests using biomarkers to identify patients.

That is no easy proposition, as only 2% of NSCLC patients will be included. But it’s a large enough group to push the field toward more testing . It also helps that Novartis just got an OK for capmatinib a few days ago, adding another drug used on the basis of a gene alteration that drives cell proliferation. As more of these drugs are approved, testing and sequencing will grow more common, allowing for better outcomes for all.

Blueprint is also likely to help that process if their next round of data for pralsetinib — now under FDA review — in RET fusion positive NSCLC highlights positive results. An application for RET-mutant medullary thyroid cancer is expected any week now.

Andrew Berens at SVB Leerink has been tracking the competition from Blueprint’s perspective, and recently noted how the matchup will be scored based on ASCO data:

We expect investor focus (on pralsetinib) to be on DOR relative to selpercatinib, which has shown median DOR of 20.3 months. However, some investors are focused on the median PFS as the relative benchmark of efficacy, with LOXO’s selpercatinib showing 18.4 months at WCLC 2019.

The FDA action on Friday serves as further validation for Lilly’s decision to turn over the oncology group to the Loxo team, led by Josh Bilenker. Lilly’s cancer team has had a lackluster performance record over the years, which Bilenker’s group was brought on to remedy. Since then, they’ve been cleaning up the pipeline and prepping new deals as Lilly looks to join big players like GSK and Sanofi, which are looking to turn things around with some fast-action cancer plays.

https://endpts.com/a-groundbreaking-cancer-dr...se-behind/


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us